Showing results (591-600 of 622) with videos related to
Sort By:
Pageof 63
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 5, 2001
Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trialA Amalfitano, A R Bengur, R P Morse, et al.The Journal of Urology|February 29, 2024
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical ProstatectomyTodd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, et al.The Journal of Urology|February 29, 2024
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future DirectionsTodd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, et al.The Journal of Urology|February 29, 2024
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical ProstatectomyTodd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2024
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)Daniel M Geynisman, Philip H Abbosh, Eric Ross, et al.Singapore Medical Journal|July 15, 2014
Ministry of Health Clinical Practice Guidelines: Diabetes MellitusS Y Goh, S B Ang, Y M Bee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2014
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicityElizabeth R Plimack, Jean H Hoffman-Censits, Rosalia Viterbo, et al.Preparative Biochemistry & Biotechnology|May 11, 2005
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditionsR Murphy, S Green, G Ritter, et al.Cancers|June 27, 2024
A Description and Safety Overview of Irreversible Electroporation for Prostate Tissue Ablation in Intermediate-Risk Prostate Cancer Patients: Preliminary Results from the PRESERVE TrialArvin K George, Ranko Miocinovic, Amit R Patel, et al.Practical Radiation Oncology|November 26, 2019
Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT TrialJohn L Gore, Marguerite du Plessis, Jingbin Zhang, et al.Pageof 63